ArticleFrontiers in oncology2025
Case Report: Diagnosing and treating gallbladder neuroendocrine neoplasms through comparative analysis: a case series and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Gallbladder. A Case Report From a Low-Resource Setting.Clinical case reports · 2026Article
- Gallbladder large cell neuroendocrine carcinoma in a patient with multiple myeloma: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder neuroendocrine neoplasms (GB-NENs) are exceedingly rare in clinical practice. To date, no large-scale, multicenter prospective studies have been conducted on this disease, resulting in a lack of established diagnostic and therapeutic experience or consensus. This case series reports seven GB-NEN patients who underwent different treatment modalities with varying outcomes. By integrating our institutional experience with previous literature, we aim to provide some therapeutic recommendations for GB-NEN patients. Methods: The clinicopathological data of seven GB-NEN patients treated at our institution between June 2013 and June 2024 were retrospectively analyzed, with a focus on their treatment courses. Results: Seven GB-NEN patients did not exhibite specific clinical manifestations or distinctive imaging features. All patients underwent surgical intervention, including radical resection in four cases. The overall survival ranged from 3 to 55 months, with a median survival of 19 months. Conclusion: GB-NENs are highly aggressive and associated with poor prognosis. We recommend: 1) Radical cholecystectomy as the primary treatment for resectable GB-NENs; 2) Platinum-based chemotherapy as the first-line regimen, with close monitoring for drug resistance; 3) Early assessment of chemosensitivity to guide further treatment decisions, postoperative chemotherapy combined with adjuvant therapies may improve surgical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.